Zusammenfassung
Calciumantagonisten hemmen am Herzen und an der glatten Muskulatur den Einstrom von Calciumionen aus dem Extrazellulärraum während des Aktionspotentials. Dies führt zu einer Vasodilatation (vorwiegend der arteriellen Gefäße) und am Herzen zu einer Abnahme von Kontraktionskraft und Herzfrequenz, die allerdings durch eine adrenerge Gegenregulation infolge Vasodilatation kompensiert wird. Bei Calciumantagonisten vom Nifedipintyp (Dihydropyridine) bewirkt dieser Kompensationsmechanismus nicht selten sogar eine reflektorische Tachykardie. Weiterhin hemmen Calciumantagonisten vom Verapamil- und Diltiazemtyp die AV-Überleitung.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Agodoa L.Y., Appel L., Bakris G.L., Beck G., Bourgoignie J., Briggs J.P. et al. for the African American Study of Kidney Disease and Hypertension (AASK) Study Group (2001): Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 285: 2719–2728.
Arzneimittelkommission der deutschen Ärzteschaft (1997): Calciumantagonisten vom 1,4-Dihydropyridin-Typ. Dtsch. Ärztebl. 22: C-1122-C-1123.
Blood Pressure Lowering Treatment Trialists’ Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955–1964.
Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L. Jr. et al. and the National High Blood Pressure Education Program Coordinating Committee (2003): The seventh report on the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289: 2560–2572.
Cohn J.N., Ziesche S.M., Loss L.E., Anderson G.F., V-HeFT Study Group (1995): Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: Results of V-HeFT VIII. Circulation 92:1–143.
European Society of Cardiology (1997): Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur. Heart J. 18:394–413.
Furberg C, Psaty B.M., Meyer J.S. (1995): Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92: 1326–1331.
Heidenreich P.A., McDonald K.M., Hastie T., Fadel B., Hagan V., Lee B.K., Hlatky M.A. (1999): Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281: 1927–1936.
Jorgensen B., Simonsen S., Endresen K., Forfang K., Vatne K., Hansen J. et al. (2000): Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J. Am. Coll. Cardiol. 35: 592–599.
Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Leiws J.B. et. al. (2001): Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345: 851–60.
Lüscher T.F., Wenzel R.R., Noll G. (1996): Calciumantagonisten in der Kontroverse: Gibt es eine rationale Differentialtherapie? Dtsch. Med. Wochenschr. 121: 532–538.
North of England Stable Angina Guideline Development Group (1996): North of England evidence based guidelines development project. BMJ 312: 827–832.
Packer M. (1989): Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N. Engl. J. Med. 320: 709–718.
Packer M., O’Connor CM., Ghali J.K., Pressler M.L., Carson P.E. et al. (1996): Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N. Engl. J. Med. 335: 1107–1114.
Pahor M., Psaty B.M., Furberg CD. (1998): Treatment of hypertensive patients with diabetes. Lancet 351: 689–690.
Pahor M., Psaty B.M., Alderman M.H., Applegate W. B., Williamson J.D., Cavazzini C, Furberg CD. (2000): Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 356: 1949–1954.
Pitt B., Byington R.P., Furberg CD., Hunninghake D. B., Mancini J., Miller M.E., Riley W. for the PREVENT Investigators (2000): Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102: 1503–1510.
Psaty B.M., Heckbert S.R., Koepsell T.D., Siscovick D.S., Raghunathan T.E. et al. (1995): The risk of myocardial infarction associated with antihypertensive drug therapies JAMA 274: 620–625.
Scholz H. (1987): Wechselwirkungen zwischen Beta-Rezeptorenblockern und Antiarrhythmika. In: Grosdanoff P. et al. (Hrsg.): Beta-Rezeptoren und Beta-Rezeptorenblocker, Walter de Gruyter & Co., Berlin New York: S. 255–271.
Staessen J.A., Fagard R., Thijs L., Celis H., Arabidze G.G. et al. (1997): Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764.
Tatti P., Pahor M., Byington R.P., Di Mauro P., Guarisco R., Strollo G., Strollo F. (1998): Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NDDM. Diabetes Care 21: 597–603.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.
The Defiant-II Research Group (1997): Doppler flow and echocardiography in functional cardiac insufficiency: Assessment of nisoldipine therapy. Results of the DEFIANT-II study. Eur. Heart J. 18: 31–40.
Tuomilehto J., Rastenyte D., Birkenhäger W.H., Thjs L., Antikainen R. et al. (1999): Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N. Engl. J. Med. 340: 677–684.
Viberti G., Wheeldon N.M. for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators (2002): Microalbuminuria reduction with valsartan in patients with typ 2 diabetes mellitus. Circulation 106: 672–678.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Scholz, H. (2004). Calciumantagonisten. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2003. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18512-0_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-18512-0_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-40188-9
Online ISBN: 978-3-642-18512-0
eBook Packages: Springer Book Archive